Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Jehad Charo

12PUBLICATIONS

104CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapy

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Apr 09, 2026

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Jose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen

|Jan 16, 2026

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.

Ignacio Melero, Neeltje Steeghs, Ulrik Lassen

|Nov 18, 2025

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Ignacio Melero, Josep Tabernero, Neeltje Steeghs

|Mar 03, 2025

Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC.

Vitalay Fomin, WeiQing Venus So, Richard Alex Barbieri

|Feb 03, 2025

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu

|Oct 18, 2024

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.

Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht

Pageof 2

Frequent Collaborators

7 joint publications

David Dejardin

7 joint publications

Volker Teichgräber

6 joint publications

Stefan Evers

6 joint publications

Christophe Boetsch

4 joint publications

Nassim Sleiman

4 joint publications

Anton Kraxner

4 joint publications

Ignacio Melero

4 joint publications

Neeltje Steeghs

4 joint publications

Caroline Ardeshir

3 joint publications

Josep Tabernero

Frequent Collaborators

7 joint publications

David Dejardin

7 joint publications

Volker Teichgräber

6 joint publications

Stefan Evers

6 joint publications

Christophe Boetsch

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on : Jun 06, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on : Feb 16, 2015

See more related videos

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on : Jun 06, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on : Feb 16, 2015

See more related videos